{"schemaVersion":"ready-scan.discovery-surface.v1","id":"urn:readyscan:corpus:buyer-question:veristat-q131986594-answer-c4405cf9ec71555384b3","key":"buyer_question:veristat-q131986594-answer-c4405cf9ec71555384b3","kind":"buyer_question","slug":"veristat-q131986594-answer-c4405cf9ec71555384b3","canonicalUrl":"https://readyscan.ai/corpus/buyer-question/veristat-q131986594-answer-c4405cf9ec71555384b3","machineUrl":"https://readyscan.ai/discovery/corpus/buyer-question/veristat-q131986594-answer-c4405cf9ec71555384b3.json","datePublished":"2026-10-25","dateModified":"2026-10-25","materialFingerprint":"fnv1a64:16f1942bb6a85bea","membershipFingerprint":"fnv1a64:85a7c038071c850f","relatedEntitySlugs":["veristat-q131986594"],"relatedSurfaceKeys":["buyer_question:veristat-q131986594-answer-1a02751483e69f2ab788","buyer_question:veristat-q131986594-answer-3412882f879455f677e8","buyer_question:veristat-q131986594-answer-34458a603e1bff48200e","buyer_question:veristat-q131986594-answer-39b32ed129c8622469be","buyer_question:veristat-q131986594-answer-518eadbfcb69743d223e","buyer_question:veristat-q131986594-answer-5fbc154d4b1ba432fb13","buyer_question:veristat-q131986594-answer-6212fedf973f6b93dd9b","buyer_question:veristat-q131986594-answer-68df9892211ef7060c6a","buyer_question:veristat-q131986594-answer-aa510bdb0ccf031ed5bb","buyer_question:veristat-q131986594-answer-cfd6628316e7e985c4b7","buyer_question:veristat-q131986594-answer-fe587a9c2de404de4138","evidence:veristat-q131986594"],"sourceIds":["ready-scan-subjects"],"provenance":[{"snapshotId":"veristat-q131986594-content-20eafb8411341c3d-snapshot","sourceId":"ready-scan-subjects","sourceRecordId":"Q131986594","sourceRevisionId":"Q131986594:content:b79eadc27cef7bcc","sourceContentHash":"fnv1a64:1dce5caf659418af","recordRevisionId":"Q131986594:content:b79eadc27cef7bcc","recordContentHash":"fnv1a64:b2a53c98a2b6b9ea","sourceCanonicalUrl":"https://www.veristat.com/","sourceModifiedAt":"2026-10-25T07:29:48.087Z","observedOn":"2026-10-25","permission":{"basis":"public_information","evidenceUrl":"https://www.veristat.com/"},"attributionUrl":"https://www.veristat.com/"}],"quality":{"method":"same_kind_unique_trigram_floor","minimumUniqueTrigramRatio":0.3,"status":"passed"},"title":"What is the CE mark, and how does it compare to FDA approval?","summary":"Cited source answers across 1 active corpus record.","question":"What is the CE mark, and how does it compare to FDA approval?","answers":[{"entitySlug":"veristat-q131986594","entityName":"Veristat","answer":"“The CE mark is the certification required to legally market a medical device or IVD in the European Economic Area (EEA), similar in purpose to FDA clearance or approval in the US, though the two follow entirely different regulatory pathways and requirements.”","sourceUrls":["https://www.veristat.com/regulatory-expertise-for-mds-ivds-and-cdx"]}]}